Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
active ingredient-free vehicle solution to DLQ01
- Development stage
- Unknown
- Lead developer
- Dermaliq Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
The active ingredient-free vehicle solution to DLQ01 is a placebo control formulation developed by Dermaliq Therapeutics for use in clinical trials evaluating DLQ01, a topical prostaglandin F2α analogue for androgenetic alopecia. It is formulated using the proprietary hyliQ® technology platform, which serves as the carrier system but contains no active pharmaceutical ingredient. In Phase 1b/2a studies, it serves as a comparator to assess the safety and efficacy of DLQ01 in men with male pattern baldness.
Beyond the preview
Go deeper on active ingredient-free vehicle solution to DLQ01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on active ingredient-free vehicle solution to DLQ01.